UPClytics
View all cases

UPC CFI 382/2025

Apr 29, 2025·EP2501384 +1 more: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Case details
Status
Case Closed
Action
Generic
Category
Costs Assessments
Parties
Claimants
Reps: Gregory Bacon (Bristows (Ireland) LLP)
Respondents
Reps: Marc Lauzeral; Schertenleib
Division
Milan CD
Technology
Organic Chemistry
Language
English
Decisions
  • 2025-07-31
    Costs onlyApplication For Costs

    Decision on costs from the Milan Central Division dated 31 July 2025 in proceedings where Novartis AG sought reimbursement of costs from Zentiva K.S. and Zentiva Portugal Lda following the dismissal of Zentiva's revocation action against EP 2 501 384. The court dismissed Novartis' costs application because Novartis failed to comply with the court's request under R. 156.1 RoP to provide substantiated evidence of costs (itemised hourly rates and hours), instead providing only a sworn general statement. The court held that: (1) once a R. 156.1 request is issued, costs can no longer be assessed equitably but only on proof; (2) confidentiality cannot be invoked to withhold cost information from the court; (3) costs for legal representation are not per se confidential under R. 262A RoP.

    Legal issues:Standard of proof for cost reimbursement after R. 156.1 RoP requestConfidentiality of legal cost informationEquitable assessment of costs versus proof-based assessment
Documents
Document titleDatePublic
Case Closure Formal Check2025-08-20Not public
Headnote-and-Keywords2025-07-31Not public
Application-For-Costs-Decision-Outcome2025-07-31Not public
DECISION2025-07-31Public
20250609 Cost recovery observations No 2 pdf a signee2025-06-09Not public
20250609 Cost recovery observations No 2 pdf a signee2025-06-09Not public
2025 06 03 - Comments on Submission by Zentiva2025-06-03Not public
Outcome of the Order2025-06-03Not public
ORDER 3 JUNE2025-06-03Public
ORDER 3 JUNE2025-06-03Public
ORDER 29 MAY2025-05-29Not public
PC005 UPC - Code of Conduct for Representatives2025-05-27Not public
PC006 Email from Schertenleib to Bristows2025-05-27Not public
20250527 Cost recovery observations v def PDFA certifie2025-05-27Not public
PC008 EC Press Release Commission Fines Teva 462 6 Million for Abusing Patent System to Delay MS Drug Competition2025-05-27Not public
PC007 UPC Milan CD 23 December 2024 Insulet v Menarini Procedural Order UPC CFI 3802024 EN2025-05-27Not public
PC002 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Opinion Advocate General2025-05-27Not public
PC001 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Judgement2025-05-27Not public
PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 6399220242025-05-27Not public
PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 6399220242025-05-27Not public
PC004 Attestation from Marc Lauzeral2025-05-27Not public
PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 6399220242025-05-27Not public
PC008 EC Press Release Commission Fines Teva 462 6 Million for Abusing Patent System to Delay MS Drug Competition2025-05-27Not public
PC002 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Opinion Advocate General2025-05-27Not public
PC001 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Judgement2025-05-27Not public
20250527 Cost recovery observations v def PDFA certifie2025-05-27Not public
PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 6399220242025-05-27Not public
PC005 UPC - Code of Conduct for Representatives2025-05-27Not public
PC007 UPC Milan CD 23 December 2024 Insulet v Menarini Procedural Order UPC CFI 3802024 EN2025-05-27Not public
PC004 Attestation from Marc Lauzeral2025-05-27Not public
PC006 Email from Schertenleib to Bristows2025-05-27Not public
Application pursuant to Rule 262A RoP2025-05-23Not public
Outcome of the Order2025-05-20Not public
ORDER 20 MAY2025-05-20Public
ORDER 20 MAY2025-05-20Public
Template-Order2025-05-20Not public
ORDER2025-05-20Not public
20250519 Cost recovery observation vdef2025-05-19Not public
20250519 deadline extension vdef2025-05-19Not public
20250519 deadline extension vdef2025-05-19Not public
ORDER 15 MAY2025-05-15Not public
Application pursuant to Rule 262A RoP2025-05-13Not public
Application pursuant to Rule 262A RoP2025-05-13Not public
Annex A - CONFIDENTIAL Annex A to Declaration of Yvonne Madawela - 13 May 20252025-05-13Not public
Comments on costs claimed2025-05-13Not public
Annex 3 - Declaration of Yvonne Madawela - 13 May 20252025-05-13Not public
Annex A - CONFIDENTIAL Annex A to Declaration of Yvonne Madawela - 13 May 20252025-05-13Not public
ORDER 6 MAY SIGNED2025-05-06Public
ORDER 6 MAY2025-05-06Public
Request for confirmation2025-05-06Not public
Request for confirmation2025-05-05Not public
2025 05 02 - Request for extension-signed2025-05-02Not public
ORDER 29 APRIL 20252025-04-29Not public
Template-Order2025-04-29Not public
Panel-Appointment2025-04-29Not public
Receipt2025-04-29Not public
Acknowledgement-of-lodging2025-04-28Not public
Annex 12025-04-28Not public
Annex 22025-04-28Not public
2025 04 28 - Application for a cost decision Novartis-signed2025-04-28Not public